TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15337003

Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography for detection of ARM
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography for morphology evaluation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preoperative detection of ARM
Number of subjects: 120
Study: 11577792

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy or chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various chemotherapy regimens
Number of subjects: 0
Study: 9205931

Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day and/or hydrochlorothiazide 12.5-25 mg/day)
Number of subjects: 3433

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3433
Study: 8035470

Group type: EXPERIMENTAL
Intervention: Therapeutic self-disclosure in couples during 10 weekly sessions
Number of subjects: 20
Study: 3663958

Group type: EXPERIMENTAL
Intervention: Interval cancers detected clinically in women under 50 years old
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: True interval tumours (31 out of 60)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-true interval tumours (29 out of 60)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of interval cancers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Shortening the screening interval
Number of subjects: 60
Study: 29957868

Group type: EXPERIMENTAL
Intervention: Camicinal 50 mg daily for a maximum of 7 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 28219403

Group type: EXPERIMENTAL
Intervention: Full KiVa program group
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: Partial KiVa (without online game) program group
Number of subjects: 1495

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1495
Study: 25643020

Group type: EXPERIMENTAL
Intervention: LF milk-based formula
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: LF soy-based formula
Number of subjects: 296

Group type: COMPARATOR
Intervention: Milk-based, lactose-containing formula
Number of subjects: 296
Study: 23721984

Group type: EXPERIMENTAL
Intervention: Yoga therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood pressure education program (sodium restriction and walking program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination program (yoga therapy and lifestyle modification)
Number of subjects: 0
Study: 21108619

Group type: EXPERIMENTAL
Intervention: E‐CPAP at 10 cmH₂O
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HF‐CPAP at 10 cmH₂O
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: V‐CPAP at 10 cmH₂O
Number of subjects: 14

Group type: COMPARATOR
Intervention: E‐CPAP vs HF‐CPAP and V‐CPAP
Number of subjects: 14
Study: 18362654

Group type: EXPERIMENTAL
Intervention: Topical mitomycin C (MMC) 0.2 mg/mL
Number of subjects: 52

Group type: COMPARATOR
Intervention: Balanced salt solution (Control)
Number of subjects: 52
Study: 17044575

Group type: EXPERIMENTAL
Intervention: Point-of-care BNP measurement
Number of subjects: 88
Study: 12760984

Group type: COMPARATOR
Intervention: Acetaminophen 10 mg/kg orally (Control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acetaminophen 10 mg/kg with 1 mg/kg of codeine orally
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 25 micro g/kg given immediately after the induction of anesthesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg/kg given IM immediately after the induction of anesthesia
Number of subjects: 120
Study: 10768327

Group type: EXPERIMENTAL
Intervention: Selective zonal ablation with excimer laser
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 26
Study: 8933184

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OTB) 600 micrograms/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study: 1425888

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS) 30 cm2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6377487

Group type: EXPERIMENTAL
Intervention: Acute excision of all burned areas (superficial dermal plus deep dermal plus subdermal burns) and grafted as quickly as possible after the accident (group A, 73 patients)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Exposure treatment until day 14 post-burn, followed by excision and grafting of non-spontaneously healed areas (group E, 76 patients)
Number of subjects: 149
Study: 31256105

Group type: EXPERIMENTAL
Intervention: Low-height table
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sofa
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bed
Number of subjects: 20
Study: 29806282

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 56
Study: 26775249

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 2819

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 2819
Study: 24852569

Group type: EXPERIMENTAL
Intervention: Oral UDCA treatment (ursodeoxycholic acid) after esophageal perfusion with DCA (250 μM) for 8 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: DCA perfusion (250 μM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 24-hour pretreatment with UDCA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: UDCA treatment
Number of subjects: 21
Study: 21856760

Group type: EXPERIMENTAL
Intervention: Oxidized LDL (oxLDL) in immune complexes (IC)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Advanced glycation end‐product (AGE)‐LDL in immune complexes (IC)
Number of subjects: 302
Study: 19680238

Group type: EXPERIMENTAL
Intervention: Doubling the portion size of fruit side dish (applesauce)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Doubling the portion size of vegetable side dishes (broccoli, carrots)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Doubling the portion size of F&V side dishes
Number of subjects: 43
Study: 17434106

Group type: EXPERIMENTAL
Intervention: Loose 125I seeds (LS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Stranded 125I seeds (RS)
Number of subjects: 64
Study: 15807285

Group type: COMPARATOR
Intervention: Repaglinide (1.0 mg tid)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nateglinide (90.0 mg tid)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (Repaglinide and Nateglinide)
Number of subjects: 46
Study: 12040357

Group type: EXPERIMENTAL
Intervention: 1800 mg of WS 1442
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 900 mg of WS 1442
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 9888474

Group type: EXPERIMENTAL
Intervention: 1 mg anastrozole
Number of subjects: 34

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination of tamoxifen and anastrozole
Number of subjects: 34
Study: 8646294

Group type: EXPERIMENTAL
Intervention: Liberate (ion-exchange chromatography purified factor VIII concentrate)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Z8 (intermediate-purity concentrate, terminally heated at 80 degrees C for 72 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Liberate and Z8
Number of subjects: 15
Study: 2105563

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 4
Study: 497090

Group type: EXPERIMENTAL
Intervention: Pivampicillin tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pivampicillin capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pivampicillin capsules and tablets
Number of subjects: 0
Study: 29668860

Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg twice daily
Number of subjects: 107

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, both every 3 weeks)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 107

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 107
Study: 27696275

Group type: EXPERIMENTAL
Intervention: Empathy Arousal
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Condemning Behavior
Number of subjects: 341

Group type: COMPARATOR
Intervention: Blaming the Bully
Number of subjects: 341
Study: 25918184

Group type: EXPERIMENTAL
Intervention: Presence of cardiometabolic disorders (MetS) at midlife
Number of subjects: 2788

Group type: EXPERIMENTAL
Intervention: 1-unit increase in the number of cardiometabolic disorders
Number of subjects: 2788

Group type: EXPERIMENTAL
Intervention: Specific cardiometabolic disorders (hyperglycaemia, central obesity, dyslipidaemia)
Number of subjects: 2788
Study: 23057761

Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention for malnourished patients
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (non-malnourished patients)
Number of subjects: 162
Study: 20471003

Group type: EXPERIMENTAL
Intervention: 30‐min night‐nap
Number of subjects: 24

Group type: COMPARATOR
Intervention: No night‐nap
Number of subjects: 24
Study: 18405147

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Acupuncture and medication
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medication (Methyl vitamin B12 250 microg, once daily)
Number of subjects: 72
Study: 16802194

Group type: EXPERIMENTAL
Intervention: Risk Eliminator group
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Risk Reducer group
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: High Risk group
Number of subjects: 287
Study: 11885342

Group type: EXPERIMENTAL
Intervention: Alcohol-free instant hand sanitizer
Number of subjects: 769

Group type: COMPARATOR
Intervention: Placebo hand sanitizer
Number of subjects: 769
Study: 9680558

Group type: EXPERIMENTAL
Intervention: 0.1 mmol of gadopentetate dimeglumine per kilogram of body weight
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.2 mmol of gadopentetate dimeglumine per kilogram of body weight
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.3 mmol of gadopentetate dimeglumine per kilogram of body weight
Number of subjects: 34
Study: 7731420

Group type: EXPERIMENTAL
Intervention: Sorbitol breath hydrogen test
Number of subjects: 40
Study: 2686956

Group type: EXPERIMENTAL
Intervention: Beclobrate (100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bezafibrate (400 mg)
Number of subjects: 20
Study: 8204997

Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline 150 mg per day
Number of subjects: 0
Study: 497671

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 11
Study: 31907004

Group type: EXPERIMENTAL
Intervention: Pharmacological conditioning group (PC) receiving MTX in alternating high and low dosages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (C) continuing with standardized treatment schedule of MTX 15 mg/week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcomes include clinical functioning, laboratory assessments, and self-reported measures
Number of subjects: 0
Study: 30418115

Group type: EXPERIMENTAL
Intervention: Major therapeutic changes (MTC)
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Worsening DAS28 at index
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: DAS28 improvements
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: No change in DAS28
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: No MTC in worsening DAS28
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: No MTC in no change in DAS28
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: No MTC in improved DAS28
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Oral steroid or nbDMARD use
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Use of nbDMARDs in previous 90 days
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Reason for not modifying therapy
Number of subjects: 941
Study: 28431766

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study: 25403846

Group type: EXPERIMENTAL
Intervention: Ibandronate treatment for 3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term clinical study of ibandronate for 6 months
Number of subjects: 0
Study: 24283768

Group type: EXPERIMENTAL
Intervention: ARVT+Jobelyn
Number of subjects: 51

Group type: COMPARATOR
Intervention: ARVT
Number of subjects: 51
Study: 20925684

Group type: EXPERIMENTAL
Intervention: Expert-led (EX) strategy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Train-the-trainer (TT) strategy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Self-study (SS) approach
Number of subjects: 92
Study: 19459079

Group type: EXPERIMENTAL
Intervention: Superoxidized solution (SOS)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (BP)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 17299118

Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention (3-month duration, daily energy deficit of -45.7 +/- 12.4%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 12
Study: 15223200

Group type: EXPERIMENTAL
Intervention: Initial Letter Fluency (ILF) task
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Semantic Category Fluency (SCF) task
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison with children with other psychopathology (N = 118)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison with healthy controls (N = 130)
Number of subjects: 20
Study: 12851990

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 0
Study: 9808499

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 1000 mg every 8 hr for CrCl >50 ml/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 1000 mg every 24 hr for CrCl of 25-50 ml/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 500 mg every day for CrCl of 10-24 ml/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 500 mg every other day after dialysis for CrCl <10 ml/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Absolute bioavailability of oral GCV
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GCV concentrations before dialysis
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GCV concentrations after dialysis
Number of subjects: 23
Study: 8694983

Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (Sonicare)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Oscillating/rotating electric toothbrush (Braun Oral‐B Plaque Remover)
Number of subjects: 116
Study: 2502905

Group type: EXPERIMENTAL
Intervention: Fast neutron radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional megavoltage external beam irradiation
Number of subjects: 0
Study: 189655

Group type: EXPERIMENTAL
Intervention: Pre‐ and post‐operative radiotherapy
Number of subjects: 398

Group type: COMPARATOR
Intervention: Post‐operative radiotherapy alone
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Single course of actinomycin D
Number of subjects: 398

Group type: COMPARATOR
Intervention: Multiple courses of actinomycin D
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Chemotherapy with vincristine and actinomycin D for 6 months
Number of subjects: 398

Group type: COMPARATOR
Intervention: Chemotherapy with vincristine and actinomycin D for 15 months
Number of subjects: 398
Study: 30926675

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy
Number of subjects: 0
Study: 27860208

Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 300 mg/day
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 450 mg/day
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study: 26088815

Group type: EXPERIMENTAL
Intervention: IDegAsp (0.5 U/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (control)
Number of subjects: 28
Study: 23681505

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 21211644

Group type: EXPERIMENTAL
Intervention: Peptide vaccine (3 nmol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cat allergen extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peptides
Number of subjects: 0
Study: 19411814

Group type: EXPERIMENTAL
Intervention: 20 g of soy protein containing 160 mg of total isoflavones
Number of subjects: 93

Group type: COMPARATOR
Intervention: Taste-matched placebo (20 g whole milk protein)
Number of subjects: 93
Study: 17192117

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 802

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 802
Study: 15493856

Group type: EXPERIMENTAL
Intervention: Continuous gastric feeding
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intermittent gastric feeding
Number of subjects: 45
Study: 11336582

Group type: EXPERIMENTAL
Intervention: Mebendazole, albendazole, and pyrantel pamoate
Number of subjects: 1000000000

Group type: EXPERIMENTAL
Intervention: Preventive chemotherapy
Number of subjects: 1000000000
Study: 9920356

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation (50 mg/day)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol and ASA combined
Number of subjects: 409

Group type: COMPARATOR
Intervention: No treatment (neither alpha-tocopherol nor ASA)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation
Number of subjects: 409
Study: 8048523

Group type: EXPERIMENTAL
Intervention: Rapid inflation (170 ml/s)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Slow inflation (0.7 ml/s)
Number of subjects: 19
Study: 3055321

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no TENS)
Number of subjects: 64
Study: 29088019

Group type: COMPARATOR
Intervention: CE 0.625 mg alone
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 5 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 10 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CE 0.3 mg/BZA 20 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CE 0.625 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CE 0.3 mg with BZA 10 or 20 mg
Number of subjects: 408
Study: 27627716

Group type: EXPERIMENTAL
Intervention: Intact PCL-retaining TKA
Number of subjects: 78

Group type: COMPARATOR
Intervention: Partial PCL-retaining TKA
Number of subjects: 78
Study: 26347109

Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m²), carboplatin (AUC 6), bevacizumab (15 mg/kg) with nitroglycerin patches (15 mg, day -2 to +2)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Paclitaxel (200 mg/m²), carboplatin (AUC 6), bevacizumab (15 mg/kg) without nitroglycerin patches
Number of subjects: 223
Study: 23734613

Group type: EXPERIMENTAL
Intervention: Computerized visuospatial memory training intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 21
Study: 20810094

Group type: EXPERIMENTAL
Intervention: Inflated tourniquet
Number of subjects: 245

Group type: COMPARATOR
Intervention: Deflated tourniquet
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 245
Study: 19037034

Group type: EXPERIMENTAL
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Subtotal Abdominal Hysterectomy (sub-TAH)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Both TAH and sub-TAH
Number of subjects: 279
Study: 16166782

Group type: EXPERIMENTAL
Intervention: 5 mg prednisolone once daily in the evening
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 14753640

Group type: EXPERIMENTAL
Intervention: Intrinsic Atrioventricular Conduction (IAVC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Permanent Ventricular Stimulation (PVS)
Number of subjects: 14
Study: 10473307

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Number of subjects: 31

Group type: COMPARATOR
Intervention: High EE relatives
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low EE relatives
Number of subjects: 31
Study: 7491344

Group type: EXPERIMENTAL
Intervention: Cyclosporin A for 6 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 43

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 43
Study: 2016615

Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg on 2 consecutive days weekly for 3 years
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: BCG for 3 years
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: BCG alternating with levamisole for 3 years
Number of subjects: 543

Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 543
Study: 7259869

Group type: EXPERIMENTAL
Intervention: Korinfar 30 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Korinfar 50 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isoptin 120 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isoptin 200 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Korinfar
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isoptin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (Korinfar and Isoptin)
Number of subjects: 11
Study: 30597042

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (dapagliflozin: ≤10 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30